Wait, Autism Might Be Treatable in Adulthood?
Okay, I need to share something that genuinely excited me this week. Scientists have been buzzing about a new study that suggests we might be able to treat autism spectrum disorder not just in children, but in fully grown adults too. And the way they did it is honestly kind of brilliant.
What's Going On in Autistic Brains?
Let me break down what's happening here in simple terms. Your brain cells (neurons) talk to each other using chemical signals. One of the most important conversation partners is something called the NMDA receptor. Think of it like a translator that helps neurons understand each other properly.
In many people with autism, these NMDA receptors aren't working quite right. They're still there, but they're not as responsive as they should be. Scientists call this "NMDA receptor hypofunction," and it's been linked not just to autism, but also to schizophrenia and certain intellectual disabilities.
The Old Approach Had Problems
Researchers have known about this NMDA issue for decades. But here's the tricky part: earlier treatments tried to boost these receptors by increasing a chemical called glycine, which activates them. They did this by blocking something called GlyT1.
Sounds reasonable, right? Well, there was a catch. GlyT1 is found all over the brain, including in areas that control breathing and movement. When you mess with those areas, you get side effects. Not ideal.
The New Target: A More Selective Approach
This is where it gets interesting. The research team, led by Director Eunjoon Kim at the IBS Center for Synaptic Brain Dysfunctions, decided to look somewhere else. They focused on a different glycine transporter called Slc6a20a (or SLC6A20 in humans).
Why this one? Because it's located mainly in brain regions responsible for thinking, learning, and memory — the cortex and hippocampus. It's not hanging out near the brainstem. This means treatments could potentially target the problem area without accidentally messing with other essential functions.
What Did They Actually Do?
The team used antisense oligonucleotides (ASOs) — basically tiny molecules that reduce the activity of the SLC6A20 gene — in mice that had autism-related mutations in genes called SHANK2 and SHANK3. (These genes are also linked to Phelan-McDermid syndrome, by the way.)
Here's what happened: reducing SLC6A20 activity restored NMDA receptor function. But it gets better.
The Results Were Remarkable
The treated mice showed improvements in social interaction, social communication, and repetitive behaviors — the core characteristics of autism in animal models. But here's the part that really caught my attention: these improvements happened in adult mice.
This is huge. It suggests that the underlying NMDA receptor dysfunction isn't fixed after brain development. The window for intervention might be much wider than we thought.
How Does It Actually Work?
The researchers dug deeper to understand the mechanism. Using sophisticated protein analysis, they found that the treatment didn't just increase or decrease protein levels. Instead, it corrected abnormal patterns in how proteins were being "switched on or off" (a process called phosphorylation).
In other words, the therapy restored the proper functioning of the existing proteins rather than dramatically changing their amounts. This seems like a more subtle and potentially safer approach.
The Human Connection
Now, I know what you're thinking: "Great, but mice aren't humans." Fair point. The scientists thought so too, so they tested the approach in human brain organoids — tiny, simplified versions of brain tissue grown from stem cells.
They used CRISPR gene editing to create human cortical organoids with SHANK2 or SHANK3 mutations. Just like in the mice, these organoids showed reduced NMDA receptor activity. And when they applied the SLC6A20-targeting ASO? The function was restored to nearly normal levels.
Director Kim put it well: "Unlike gene re-expression strategies, SLC6A20 inhibition works by modulating endogenous signaling pathways and may offer a more practical therapeutic route."
Practical Benefits
Another encouraging finding: a single administration of the ASO remained effective for at least 8 weeks with no detectable adverse effects in the mice. That's a long-lasting effect from one treatment.
What Does This Mean for the Future?
I want to be careful here. This is early-stage research. We're talking about mice and lab-grown human brain tissue, not human clinical trials yet. The path from "promising discovery" to "available treatment" is long and uncertain.
But here's why I'm genuinely excited:
First, it suggests that NMDAR dysfunction in autism may be treatable in adulthood. That challenges assumptions that developmental windows close permanently.
Second, it identifies a new, more selective target that might avoid the side effects of previous approaches.
Third, the approach worked in human tissue, which is a crucial step toward eventually translating this to people.
And finally, because reduced NMDAR activity is involved in several conditions — autism, schizophrenia, intellectual disability — this same strategy might eventually help many different patient populations.
My Take
I've covered a lot of autism research over the years, and I'll be honest: most findings that seem promising in mice don't make it to humans. The biology is just incredibly complex.
But this one feels different. The fact that they found a more selective target, demonstrated benefits in adult animals, and successfully replicated the effect in human brain tissue gives me cautious optimism.
What I find particularly hopeful is the idea that we're not trying to rewire the brain from scratch. We're restoring a communication pathway that already exists and may simply need a little adjustment. That feels more achievable than some of the more ambitious approaches I've read about.
We'll need to wait for clinical trials to know if this works in people. But for now, this research offers a genuinely new avenue worth watching.
Source: ScienceDaily — https://www.sciencedaily.com/releases/2026/08/260805082508.htm